Allergan Licenses Phase I Skin Cancer Drug from Peplin

By Business Review Editor

Pharma Deals Review: Vol 2002 Issue 31 (Table of Contents)

Published: 2 Dec-2002

DOI: 10.3833/pdr.v2002.i31.966     ISSN: 1756-7874

Section: Licensing



Allergan acquired the rights to PEP 005 product useful for treating nonmelanoma skin cancer and actinic keratosis from Peplin Biotech...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details